Monte Rosa Therapeutics (GLUE) vs Sana Biotechnology (SANA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Monte Rosa Therapeutics (GLUE) has outperformed Sana Biotechnology (SANA) over the past year, gaining 33.9% versus a loss of 38.4%. Over five years, GLUE leads with a -51.3% price change compared with -86.6% for SANA. Monte Rosa Therapeutics is the larger company by market cap ($878.7 million vs $835.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GLUE | SANA |
|---|---|---|
| Share price | $10.30 | $2.79 |
| Market cap | $878.73M | $835.22M |
| 1-day change | -0.19% | 0.00% |
| YTD return | -34.18% | -31.45% |
| 1-year return | +33.85% | -38.41% |
| 5-year return | -51.32% | -86.58% |
| EPS (TTM) | $-1.75 | $-0.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $25.77 | $6.55 |
| 52-week low | $8.53 | $2.61 |
| Distance from 52-week high | -60.03% | -57.40% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +171.84% | +202.15% |
| Average volume | 1.33M | 3.13M |
| Shares outstanding | 85.31M | 299.36M |
| Employees | 173 | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GLUE has outperformed SANA by 72.3 percentage points over the past year.
About Monte Rosa Therapeutics
GLUE stock →Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 173 employees
About Sana Biotechnology
SANA stock →Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees
GLUE vs SANA FAQ
Which is bigger, Monte Rosa Therapeutics or Sana Biotechnology?
Monte Rosa Therapeutics (GLUE) is larger, with a market capitalization of $878.73M compared with $835.22M for Sana Biotechnology (SANA).
Which stock has performed better over the past year, GLUE or SANA?
GLUE returned +33.85% over the past 12 months, compared with -38.41% for SANA (price return, excluding dividends). Past performance does not predict future results.
Are Monte Rosa Therapeutics and Sana Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.